News Summary: Easy-to-use, compact analyzer makes rheological insights more accessible to quality testing laboratories and material production facilities in batteries, pharmaceuticals, food, consumer goods, and other industries. Powered by RheoGuide™ Software, a streamlined, modern touchscreen user interface with built-in self-guided methods, workflows, and training applications to simplify rheological testing for all users. Superior...Read more
LONDON / Oct 08, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. “LivaNova’s Board of Directors is pleased to welcome Susan Podlogar,” said William Kozy, Chair of the Board. “Susan is a visionary leader with...Read more
New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla. / Oct 08, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML). “AML...Read more
GOLETA, Calif. / Oct 08, 2024 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has commenced the U.S. market release of the Inogen® Rove 4™ Portable Oxygen Concentrator. With an additional, fourth flow setting delivering up to 840ml/min of medical grade oxygen, in a lightweight user-friendly design of less than 3...Read more
LEXINGTON, Mass. and SCHENECTADY, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, and Prxcision, Inc., innovators behind the real-time AI-powered decision support platform pRxcision®, have announced a co-marketing collaboration intended to deliver a revolutionary solution for patients suspected of bloodstream infections...Read more
NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest...Read more
BERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today increasing demand from existing and prospective laboratory partners for its enhanced ColoAlert product that has been launched in July 2024 and is currently being commercialized across Europe and in...Read more
EXTON, Pa., Oct. 7, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPHI Worldwide in Milan, Italy to showcase leadership and expertise on industry challenges and trends in packaging and containment. This year, West will highlight its industry expertise through a technical-focused...Read more
New Multiphoton Microscopy Module Enables Millisecond Neural Event Imaging at Single Neuron Resolution CHICAGO / Oct 07, 2024 / Business Wire / At the Neuroscience 2024 conference, Bruker Corporation (Nasdaq: BRKR) today announced the release of the OptoVolt™ module to further expand the advanced neuroscience research capabilities on Bruker’s Ultima multiphoton microscope platform. OptoVolt accelerates imaging speeds to beyond 1000 frames...Read more
A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by...Read more
Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market COCONUT GROVE, Fla. and MIAMI, Oct. 7, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced a significant expansion of its exclusive e-commerce distribution...Read more
Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK)...Read more
Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company has sold...Read more
Analysis of 35,000 patients tested with Nodify Lung® Nodule Risk Assessment in a real-world setting to be presented at CHEST 2024 and launch of a new clinical study designed to expand data package LOUISVILLE, Colo. / Oct 07, 2024 / Business Wire / Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston,...Read more
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya’s platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial...Read more
MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization...Read more
TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it is providing an...Read more
Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024 Enters U.S. Health Market in October with IM8, a New Health and Wellness Brand Re-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the second quarter ended...Read more
ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cryoablation, radiofrequency, and microwave) wins EUSOBI Young Physician Scientist Competition – cryoablation demonstrates 94% complete rate of ablation IceCure exhibited ProSense® and conducted hands-on demos and Q&A sessions...Read more
LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the third quarter 2024. Recent Financial and Operational Highlights (unaudited) Achieved third quarter total revenue of $2.0 million, representing an increase of 35% compared to the...Read more
LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics...Read more
Submitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants on Tuesday, November 5th at 9:00 AM U.S. ET Presentations of Beyond Cancer’s two full posters will take place on November 8th and 9th at the SITC Annual Meeting; ePublications of the posters will be available November 7th Therapeutic efficacy of Low Volume (<1L) UNO demonstrated in both mice and rat tumor models HAMILTON,...Read more
DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM...Read more
Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening test Company expects to launch Cologuard Plus test with Medicare coverage and guideline inclusion in 2025 MADISON, Wis. / Oct 04, 2024 / Business Wire /...Read more
WILMINGTON, Mass. / Oct 03, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researchers from across the globe, will take place...Read more
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima’s UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad’s ability to offer...Read more
LATHAM, N.Y. / Oct 03, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter...Read more
132 patients enrolled TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic...Read more
HOLLISTON, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ implantable telemetry platform, and the VivaMARS™ activity...Read more
HENDERSON, Nev., Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management. The session,...Read more
ROSELAND, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that iHeal Pain Center has adopted the CompuFlo® Epidural System following successful epidural steroid injection (ESI) procedures by Dr. Desai, DO. Dr. Desai has performed six cervical and two lumbar ESI procedures using the...Read more
Calgary, Alberta--(Newsfile Corp. - October 3, 2024) - Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF), a leader in portable NMR machines and MRI technology for industrial and research applications, is pleased to announce its participation at the upcoming Cantech Letter Investment Conference on Wednesday, October 9, 2024 in Toronto Ontario. Sean Krakiwsky, Chief Executive Officer of Nanalysis Scientific Corp. will be doing an...Read more
MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company’s Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the...Read more
DALLAS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the completion of a proof-of-concept module of its wound measurement technology that calculates the total body surface area (“TBSA”) of a burn. This technology, which is currently...Read more
The company has achieved EBIDTA positive on a go-forward cash basis REDWOOD CITY, CA / ACCESSWIRE / October 3, 2024 / Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company that is reshaping the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today reports compelling financial and strategic advancements that will propel the company towards...Read more
RESEARCH TRIANGLE PARK, N.C. / Oct 02, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights. IQVIA AI Assistant is a user-friendly,...Read more
APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass. / Oct 02, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for...Read more
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company announced today that its LEGION Hinged Knee (HK) System is now available in the United States with proprietary OXINIUM (Oxidized Zirconium) implant technology that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both.1-11 Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a...Read more
Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business MUNICH / Oct 02, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker’s biophysical...Read more
Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass. / Oct 02, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize Logica® to progress critical brain disease research. “We are excited to partner with Lundbeck as they...Read more
AUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio. Globus has introduced several new system extensions so far in 2024 and received 510(k) clearance from the U.S. Food and Drug Administration for its first suture-based product, TENSOR™ Suture Button System. Newly launched,...Read more
NEW YORK / Oct 02, 2024 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that the first patients in the United States have successfully undergone breast augmentation with Motiva® Implants. “With the FDA approval last week, we are experiencing high demand for Motiva...Read more
MINNEAPOLIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller...Read more
GARDEN CITY, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced entering a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting firm. This partnership is...Read more
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent no. 12,104,212, entitled “Personalized Methods for Detecting...Read more
Approval provides new catalyst for AtriCure’s international growth MASON, Ohio / Oct 01, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval to sell the EnCompass® Clamp in CE-marked countries in the European Union,...Read more
The platform provides a versatile pre-filled and pre-loaded on-body solution, suitable for highly viscous biological drugs PIOMBINO DESE, Italy / Oct 01, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option...Read more
Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC...Read more
The Pounce™ Thrombectomy Platform can now be used to remove clot from peripheral arteries as small as 2mm up to as large as 10 mm in diameter, broadening the platform's clinical utility and significantly expanding its addressable market EDEN PRAIRIE, Minn. / Oct 01, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food...Read more
SINGAPORE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the Agency for Science, Technology, and Research (A*STAR), and Macrogen, today announced the opening of a state-of-the-art joint laboratory at A*STAR Genome Institute of Singapore (A*STAR GIS) in Singapore. This new facility, located on Level 5 of the Genome building at...Read more
LYON, France, October 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the Company’s proprietary Focal One® robotic high-intensity focused ultrasound (HIFU) technology for the treatment of benign prostatic hyperplasia (BPH). “We’ve been offering targeted HIFU ablation to prostate cancer patients for more...Read more
The De Novo medical device application for DrugSorb™-ATR is eligible for FDA priority review as an FDA Breakthrough Designated Device for this indication The Health Canada Medical Device License application is ready for submission, pending the expected receipt of Medical Device Single Audit Program (MDSAP) certification in the near future Expecting FDA and Health Canada decisions in 2025 PRINCETON, N.J., Oct. 01, 2024 (GLOBE...Read more
The SAFE MRI ECMO study evaluated the use of ultra-low-field portable MR imaging on ICU patients undergoing extracorporeal membrane oxygenation (ECMO) with an elevated risk of acute brain injury (ABI) GUILFORD, Conn. / Oct 01, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging...Read more
Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health NATICK, Mass. / Oct 01, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed...Read more
The new contract significantly expands Dario's footprint with more than a million eligible members beginning January 2025 NEW YORK, Oct. 1, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national Medicare Advantage health plan (the "Plan") to launch its behavioral health solution for the Plan members beginning in...Read more
Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS Recent study1 published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort Primary endpoint results from OCT B-Series pivotal...Read more
StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its second quarter financial results for the three and six...Read more
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts. GPS Marine delivers critical maritime services across the UK’s inland...Read more
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the AirTouch™ N30i. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring...Read more
ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE...Read more
Venlo, the Netherlands, Sept. 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics. The instrument and accessories are 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe. QIAcuityDx streamlines clinical testing by providing highly...Read more
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held in...Read more
Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly BILLERICA, Mass. / Sep 30, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it is making its Simoa® p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer’s Disease (AD)...Read more
Company to leverage capital and Valor’s expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™ Purchase price of US$9.51 represents a 20% premium over 30-day VWAP of BrainsWay’s American Depositary Shares Valor provides growth equity to technology-enabled companies and currently has $18.9B in assets under management BURLINGTON, Mass. and...Read more
SAN DIEGO, CA / ACCESSWIRE / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor...Read more
Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable reduction in tumor size after three weeks. Treatment options for cancer in small exotic animals remain limited, and the current standard of care—surgical tumor removal—can be too invasive for exotic animals. Dr. Korenko commented, “While we have...Read more
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz., Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted...Read more
TORONTO and DALLAS, Sept. 30, 2024 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce the closing of its non-brokered private placement of common shares in the capital of the Company ("Common Shares") announced on September 10, 2024 (the "Offering"). The Company issued 23,470,560 Common Shares at a price of $0.42 per...Read more
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for...Read more
Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy® in Phase 2 and improvement in DGI scores from Phase 1 to end of treatment at week 14 Confirms the therapeutic benefits of PoNS Therapy for gait deficit improvement in people with MS NEWTOWN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...Read more
NAPERVILLE, Ill., Sept. 28, 2024 /PRNewswire/ -- Endotronix, an Edwards Lifesciences company (NYSE: EW), today announced the one-year clinical results from PROACTIVE-HF, evaluating outcomes for the Cordella Pulmonary Artery (PA) Sensor System. The data were shared as part of the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The data demonstrated that the 456 patients managed with Cordella in the study experienced a...Read more
MARLBOROUGH, Mass., Sept. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System, which is indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF), is a novel alternative to standard-of-care thermal...Read more
APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopy Successful launch in Japan follows recent reimbursement approval Approvals across APAC including China and Australia broaden reach for patients GALWAY, Ireland and SYDNEY, Sept. 27, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of...Read more
In the study, patients with lower-stage Brigham and Women's Hospital (BWH) T1-T2a cutaneous squamous cell carcinoma (SCC) tumors were further stratified into distinct groups of those with more or less favorable survival by the DecisionDx-SCC test, including in the T2a immunosuppressed patient subset which showed a higher rate of metastasis FRIENDSWOOD, Texas / Sep 27, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a...Read more
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supineat 12 months compared with baseline. 82.0% of patients who completed a polysomnography at 12 months had an AHI below 15, and 67.4% of patients...Read more
Total MRI scan volume at the HMCA-managed sites increased 11% to 209,327 scans for the fiscal year ending June 30, 2024 as compared to the prior year. Cash and Cash Equivalents increased 10% to $56.3 million at June 30, 2024 versus the previous fiscal year. Total Revenues - Net increased by 4% to $102.9 million for the fiscal year ended June 30, 2024 versus the previous fiscal year. Income from Operations increased 12%...Read more
LIFE Financing and Concurrent Private Placement to Include Common Shares Only and no Warrants Toronto, Ontario--(Newsfile Corp. - September 27, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it will be conducting a non-brokered listed issuer...Read more
Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 Avenue Capital, current insiders, and select group of healthcare-focused investment funds participated in the equity offering GARDEN CITY, N.Y., Sept. 27,...Read more
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company’s clinical study plan. The clinical studies are a key element of the Company's 510(k) submission,...Read more
FRANKLIN LAKES, N.J., Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operating room. Hospital drug diversion occurs when a health care worker "diverts" opioids or other...Read more
Provides patients with certain chronic lung conditions and retained secretions added comfort, user-friendly touch screen and unique garment design options Developed in consultation with clinicians and patients for an enhanced user experience The Vest uses High Frequency Chest Wall Oscillation therapy, a therapy for which Hillrom, now part of Baxter, has been a pioneer and industry leader BOSTON / Sep 26, 2024 / Business Wire / Baxter...Read more
Highlights include new safety and efficacy data of Barrigel™ rectal spacer, the first and only sculptable rectal spacer1-3 Teleflex to host Barrigel™ Educational Symposium featuring a physician panel discussion on the Science of Personalized Spacing with Barrigel™ rectal spacer WAYNE, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced...Read more
Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE-marking under the European Union's new In-Vitro Diagnostic Medical Devices Regulation (IVDR). This certification includes the widely-used QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and...Read more
CHICAGO / Sep 26, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda’s oncology research and development efforts. After an initial collaboration that leveraged Tempus’...Read more
IRVINE, Calif. / Sep 26, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces...Read more
NEW YORK / Sep 26, 2024 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast...Read more
NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active ingredient in Ozempic®/Wegovy®, with twice-yearly administration Study will represent the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Sep 26, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the...Read more
IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. enVVeno expects to grant the underwriter a 30-day option...Read more
VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to provide an update on its flagship sublingual Cladribine drug formulation program for the treatment of Multiple Sclerosis ("MS"), broad sublingual patent application for the use of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, and investor relations...Read more
GALWAY, Ireland and CHICAGO, Sept. 25, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39th Annual Meeting in Chicago the commercial launch of several software, hardware, and imaging innovations. These enhancements are designed to advance AiBLE™, the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software...Read more
| Company | Change | Last Trade |
|---|---|---|
| Waters | 8.73 2.49 | $358.65 |
| Intuitive Surgical | 6.50 1.38 | $477.73 |
| McKesson | 6.47 1.34 | $490.14 |
| IDEXX Laboratories | 5.12 1.08 | $477.54 |
| ResMed | 5.01 2.16 | $237.30 |
| Stryker | 4.00 1.16 | $349.14 |
| Masimo | 3.76 2.77 | $139.43 |
| Medpace | 2.90 0.87 | $335.50 |
| ICU Medical | 2.47 1.39 | $179.67 |
| Natera | 2.46 1.92 | $130.66 |
| PROCEPT BioRobotics | 2.21 3.17 | $71.83 |
| Glaukos | 2.06 1.63 | $128.48 |
| IQVIA | 1.61 0.71 | $226.98 |
| Lantheus | 1.49 1.40 | $108.09 |
| STERIS | 1.32 0.58 | $227.34 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE